search
Back to results

Safety and Pharmacokinetic Study of Y242 in Adult Subjects (Y242-01)

Primary Purpose

Obesity

Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
Y242
0.9% saline
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity, Peptide YY, Food intake, Safety, Pharmacokinetics

Eligibility Criteria

18 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Adult males aged 18 to 50 years inclusive with BMI between 23.0 and 30.0 kg/m^2 inclusive;
  • Subjects who are healthy as determined by pre study medical history, physical examination and 12 lead ECG;
  • Subjects whose clinical laboratory test results are either within the normal range or if outside this range the abnormalities are judged to be not clinically relevant and are acceptable to the Investigator;
  • Subjects who are negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) I and II tests at screening;
  • Subjects who are negative for drugs of abuse and alcohol tests at screening and admissions;
  • Subjects who are non-smokers for at least 3 months preceding screening;
  • Subjects who agree to use medically acceptable methods of contraception for at least 3 months after study drug administration;
  • Subjects who are able and willing to give written informed consent.

Exclusion Criteria:

  • Subjects who do not conform to the above inclusion criteria;
  • Subjects who have a clinically relevant history or presence of gastrointestinal (especially associated with vomiting), respiratory, renal, hepatic, haematological, lymphatic, neurological (especially if associated with balance disorders or vomiting e.g. migraine or labyrinthitis), cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders;
  • Subjects who have a clinically relevant surgical history;
  • Subjects who have a clinically relevant family history;
  • Subjects who have a history of relevant atopy;
  • Subjects who have a history of relevant drug hypersensitivity;
  • Subjects who have a history of alcoholism;
  • Subjects who have a history of drug abuse;
  • Subjects who have a history of migraine;
  • Subjects who consume more than 21 units of alcohol a week (unit = 1 glass of wine (125 mL) = 1 measure of spirits = ½ pint of beer);
  • Subjects who have a significant infection or known inflammatory process on screening;
  • Subjects who have acute gastrointestinal symptoms at the time of screening or admission (e.g. nausea, vomiting, diarrhoea, heartburn);
  • Subjects who have an acute infection such as influenza at the time of screening or admission;
  • Subjects who have used prescription drugs within 4 weeks of first dosing;
  • Subjects who have used over the counter medication excluding routine vitamins and paracetamol but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as not clinically relevant by the Principal Investigator and Sponsor;
  • Subjects who have donated blood or blood products within 3 months of Day -2 (admission);
  • Subjects who have used any investigational drug in any clinical trial within 3 months of Day -2 (admission);
  • Subjects who have received the last dose of investigational drug greater than 3 months ago but who are on extended follow-up;
  • Subjects who have previously received Y242;
  • Subjects who are vegans or have any dietary restrictions;
  • Subjects who cannot communicate reliably with the Investigator;
  • Subjects who are unlikely to co-operate with the requirements of the study;
  • History or evidence of abnormal eating behaviour, as observed through the Dutch Eating Behaviour (DEBQ) and SCOFF questionnaires at screening.

Sites / Locations

  • PAREXEL Early Phase Clinical Unit

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Placebo Comparator

Arm Label

2mg Y242 (Part A)

7.5mg Y242 (Part A)

15mg Y242 (Part A)

30mg Y242 (Part A)

60mg Y242 (Part A)

90mg Y242 (Part A)

Placebo - Part A

60mg Y242 (Part B1)

90mg Y242 (Part B2-B4)

Placebo - Part B

Arm Description

Y242 single dose, subcutaneous

Y242 single dose, subcutaneous

Y242 single dose, subcutaneous

Y242 single dose, subcutaneous

Y242 single dose, subcutaneous

Y242 single dose, subcutaneous

0.9% saline

Y242 single subcutaneous dose, administered once a week for 5 weeks

Y242 single subcutaneous dose, administered once a week for 5 weeks

0.9% saline

Outcomes

Primary Outcome Measures

Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
A treatment-emergent AE (TEAE) as defined as an AE that started after administration of IMP; in Part B this was an AE that started after the first dose of IMP. Adverse events with onset prior to dosing were considered as pre-treatment AEs.

Secondary Outcome Measures

Body Weight
Summary of Time-Matched % Change from Baseline in Body Weight (Baseline = Day -1) following multiple dose of Y242 (Part B)

Full Information

First Posted
December 22, 2011
Last Updated
January 19, 2021
Sponsor
Imperial College London
Collaborators
Medical Research Council
search

1. Study Identification

Unique Protocol Identification Number
NCT01515319
Brief Title
Safety and Pharmacokinetic Study of Y242 in Adult Subjects
Acronym
Y242-01
Official Title
A Randomised, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Y242 in Adult Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
April 2012 (Actual)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
February 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
Collaborators
Medical Research Council

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obesity causes 600 premature deaths per week in the UK and existing treatments are not effective. When humans eat, the bowels naturally secrete chemicals into the bloodstream which make people feel full and which stop eating. One of these chemicals is known as Peptide YY (PYY). The investigators have previously shown that injections of PYY reduce appetite and food intake in human volunteers. The investigators have now developed a very similar chemical, Y242, as a treatment for obesity. Y242 has been tested in animals and has been shown to be safe, to reduce their appetite, and to last for much longer than PYY itself. This study will test Y242 to ensure that it is well tolerated in humans, and to see how long it lasts in the blood stream after being injected under the skin. It will also look for any effects on appetite.
Detailed Description
Obesity causes 600 premature deaths per week in the UK and existing treatments are less than ideal. Intravenous infusion of a hormone called PYY reduces food intake but its effects only last for a few hours and it can cause nausea. Y242 is a longacting analogue of PYY. Given subcutaneously in rodents, it has a profile of action of at least 72 hours and strongly inhibits food intake. It causes weight loss without behavioural effects. With MRC funding, Y242 has passed Good Laboratory Practice toxicology testing and the present proposal is a first in human study to investigate its safety, tolerability and pharmacokinetics in overweight but otherwise healthy men. The study is a combined single ascending dose (part A) and multiple ascending dose (part B) Phase 1 investigation. The primary objective is to investigate safety and tolerability. The secondary objective is to assess Y242's pharmacokinetic (PK) profile. Possible effects on food consumption will be explored. For part A up to 48 subjects are planned, with up to 40 subjects for part B. In each part subjects are divided into groups, each of which is dosed with the same level, starting with a single dose (part A) much lower than is expected to cause an effect. Subjects are admitted to a Unit so they can be closely observed for adverse effects and safety tests, blood concentrations of the drug and food and liquid intake and output will be monitored. Subjects are allocated at random (like tossing a coin) to receive Y242 or placebo (dummy). Safety, tolerability and pharmacokinetic data will be summarised and available results considered in deciding dose escalation, with stopping rules designed to enable us to explore the relationship between dose and adverse effect (eg nausea) without causing unacceptable nausea or other symptoms in the volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Peptide YY, Food intake, Safety, Pharmacokinetics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Part A was a single blind, randomised, placebo controlled, single ascending dose (SAD) study. Part B was a double blind, randomised, placebo controlled, multiple ascending dose (MAD) study
Masking
ParticipantInvestigator
Masking Description
Part A: Treatments were administered single-blind; subjects were blinded with regard to treatment and clinical staff remained blinded with regard to treatment until the Safety Committee meeting. Part B was double blind.
Allocation
Randomized
Enrollment
68 (Actual)

8. Arms, Groups, and Interventions

Arm Title
2mg Y242 (Part A)
Arm Type
Experimental
Arm Description
Y242 single dose, subcutaneous
Arm Title
7.5mg Y242 (Part A)
Arm Type
Experimental
Arm Description
Y242 single dose, subcutaneous
Arm Title
15mg Y242 (Part A)
Arm Type
Experimental
Arm Description
Y242 single dose, subcutaneous
Arm Title
30mg Y242 (Part A)
Arm Type
Experimental
Arm Description
Y242 single dose, subcutaneous
Arm Title
60mg Y242 (Part A)
Arm Type
Experimental
Arm Description
Y242 single dose, subcutaneous
Arm Title
90mg Y242 (Part A)
Arm Type
Experimental
Arm Description
Y242 single dose, subcutaneous
Arm Title
Placebo - Part A
Arm Type
Placebo Comparator
Arm Description
0.9% saline
Arm Title
60mg Y242 (Part B1)
Arm Type
Experimental
Arm Description
Y242 single subcutaneous dose, administered once a week for 5 weeks
Arm Title
90mg Y242 (Part B2-B4)
Arm Type
Experimental
Arm Description
Y242 single subcutaneous dose, administered once a week for 5 weeks
Arm Title
Placebo - Part B
Arm Type
Placebo Comparator
Arm Description
0.9% saline
Intervention Type
Drug
Intervention Name(s)
Y242
Intervention Description
Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)
Intervention Type
Drug
Intervention Name(s)
0.9% saline
Intervention Description
Identical volume to that of Y242
Primary Outcome Measure Information:
Title
Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
Description
A treatment-emergent AE (TEAE) as defined as an AE that started after administration of IMP; in Part B this was an AE that started after the first dose of IMP. Adverse events with onset prior to dosing were considered as pre-treatment AEs.
Time Frame
Up to 73 days
Secondary Outcome Measure Information:
Title
Body Weight
Description
Summary of Time-Matched % Change from Baseline in Body Weight (Baseline = Day -1) following multiple dose of Y242 (Part B)
Time Frame
up to 32 day

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
Adult males aged 18 to 50 years inclusive with BMI between 23.0 and 30.0 kg/m^2 inclusive
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult males aged 18 to 50 years inclusive with BMI between 23.0 and 30.0 kg/m^2 inclusive; Subjects who are healthy as determined by pre study medical history, physical examination and 12 lead ECG; Subjects whose clinical laboratory test results are either within the normal range or if outside this range the abnormalities are judged to be not clinically relevant and are acceptable to the Investigator; Subjects who are negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) I and II tests at screening; Subjects who are negative for drugs of abuse and alcohol tests at screening and admissions; Subjects who are non-smokers for at least 3 months preceding screening; Subjects who agree to use medically acceptable methods of contraception for at least 3 months after study drug administration; Subjects who are able and willing to give written informed consent. Exclusion Criteria: Subjects who do not conform to the above inclusion criteria; Subjects who have a clinically relevant history or presence of gastrointestinal (especially associated with vomiting), respiratory, renal, hepatic, haematological, lymphatic, neurological (especially if associated with balance disorders or vomiting e.g. migraine or labyrinthitis), cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders; Subjects who have a clinically relevant surgical history; Subjects who have a clinically relevant family history; Subjects who have a history of relevant atopy; Subjects who have a history of relevant drug hypersensitivity; Subjects who have a history of alcoholism; Subjects who have a history of drug abuse; Subjects who have a history of migraine; Subjects who consume more than 21 units of alcohol a week (unit = 1 glass of wine (125 mL) = 1 measure of spirits = ½ pint of beer); Subjects who have a significant infection or known inflammatory process on screening; Subjects who have acute gastrointestinal symptoms at the time of screening or admission (e.g. nausea, vomiting, diarrhoea, heartburn); Subjects who have an acute infection such as influenza at the time of screening or admission; Subjects who have used prescription drugs within 4 weeks of first dosing; Subjects who have used over the counter medication excluding routine vitamins and paracetamol but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as not clinically relevant by the Principal Investigator and Sponsor; Subjects who have donated blood or blood products within 3 months of Day -2 (admission); Subjects who have used any investigational drug in any clinical trial within 3 months of Day -2 (admission); Subjects who have received the last dose of investigational drug greater than 3 months ago but who are on extended follow-up; Subjects who have previously received Y242; Subjects who are vegans or have any dietary restrictions; Subjects who cannot communicate reliably with the Investigator; Subjects who are unlikely to co-operate with the requirements of the study; History or evidence of abnormal eating behaviour, as observed through the Dutch Eating Behaviour (DEBQ) and SCOFF questionnaires at screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Bloom DSc, MD FRCP
Organizational Affiliation
Imperial College London
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
John Lambert, MBBS PhD
Organizational Affiliation
Parexel
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tricia Tan BSc MRCP, MB ChB
Organizational Affiliation
Imperial College London
Official's Role
Study Director
Facility Information:
Facility Name
PAREXEL Early Phase Clinical Unit
City
London
ZIP/Postal Code
HA1 3UJ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Pharmacokinetic Study of Y242 in Adult Subjects

We'll reach out to this number within 24 hrs